Objective-Adipose tissue (AT) dysfunction associated with obesity or aging is a major cause for lipid redistribution and the progression of cardiometabolic disorders. Our goal is to decipher the contribution of human AT microvascular endothelial cells (ECs) in the maintenance of fatty acid (FA) fluxes and the impact of senescence on their function. Approach and Results-We used freshly isolated primary microvascular ECs from human AT. Our data identified the endothelial FA handling machinery including FATPs (FA transport proteins) FATP1, FATP3, FATP4, and CD36 as well as FABP4 (FA binding protein 4). We showed that PPARγ (peroxisome proliferator-activated receptor gamma) regulates the expression of FATP1, CD36, and FABP4 and is a major regulator of FA uptake in human AT EC (hATEC). We provided evidence that endothelial PPARγ activity is modulated by senescence. Indeed, the positive regulation of FA transport by PPARγ agonist was abolished, whereas the emergence of an inflammatory response was favored in senescent hATEC. This was associated with the retention of nuclear FOXO1 (forkhead box protein O1), whereas nuclear PPARγ translocation was impaired. Conclusions-These data support the notion that PPARγ is a key regulator of primary hATEC function including FA handling and inflammatory response. However, the outcome of PPARγ activation is modulated by senescence, a phenomenon that may impact the ability of hATEC to properly respond to and handle lipid fluxes. Finally, our work highlights the role of hATEC in the regulation of FA fluxes and reveals that dysfunction of these cells with accelerated aging is likely to participate to AT dysfunction and the redistribution of lipids. Visual Overview-An online visual overview is available for this article.
M
etabolic and cardiovascular disorders, seen as a leading cause for morbidity and mortality, are commonly associated with accumulation of fat mass in the central part of the body. White adipose tissue (WAT) dysfunction leading to incapacity to store the excess of fatty acids (FA) into neutral triglycerides, is recognized as a major contributor of type 2 diabetes mellitus because it promotes ectopic FA deposition and toxicity (lipotoxicity) in other metabolically active tissues such as the liver and skeletal muscle, leading to insulin resistance. 1 In turn, type 2 diabetes mellitus represents a strong risk factor for cardiovascular diseases and microvascular complications associated with profound dysfunction of endothelial cells (ECs). 2 Premature aging of the WAT may be a causal event of its dysfunction. 3 Indeed, obesity and aging share common life-threatening disorders such as type 2 diabetes mellitus, hypertension, and cardiovascular diseases. In both conditions, WAT dysfunction is associated with an accumulation of senescent cells including progenitor cells that become unable to produce new fat cells 4, 5 and consequently alters the ability of WAT to properly adapt to the influx of FA. Cellular senescence is at first a physiological mechanism in response to various stimuli such as DNA damage, oncogene activity, or metabolic stress, preventing the expansion of damaged cells. In particular, these cells, that become unable to proliferate, are characterized by the overexpression or activity of cell cycle inhibitors including the organismal aging marker P16INK4 (CDKN2A). 6 Although senescence could be protective against the development of diseases such as cancer, it is likely that accumulation of senescent cells may have deleterious impact.
FA, naturally stored as triglycerides in adipocytes, have to be channeled through the microvascular endothelium according to mechanisms that remain poorly understood. Transport of FA through nonfenestrated microvascular endothelium is believed to involve membrane FATPs (FA transporters; FATPpm, CD36) and cytoplasmic FABPs (FA binding proteins). 7, 8 In the heart and skeletal muscle with high energy needs, FA transport through endothelial expression of FATP3 and FATP4 are locally regulated by VEGF-B (vascular endothelial growth factor B). Importantly, blockade of VEGF-B signaling reverses insulin resistance in animal models of obesity. 9, 10 Noticeably, this regulation was not observed in WAT ECs supporting that the mechanisms involved in FA handling vary across vascular beds. In WAT endothelium, other factors including PPARγ (peroxisome proliferator-activated receptor gamma) have been proposed to play a role. 8, 11 PPARγ is a ligand-activated transcription factor and the master regulator of adipogenesis. 12 Polymorphisms and mutations in PPARγ gene are associated with the development of metabolic syndrome, illustrating its critical role in lipid homeostasis and metabolism. [13] [14] [15] PPARγ-dependent pathway activation by thiazolidinediones is efficient to decrease blood glucose in diabetic subjects, restore insulin sensitivity, limit dyslipidemia, prevent ectopic deposition of FA, and hamper inflammation. However, these drugs have dramatic side effects leading to restriction in the United States and withdrawal in Europe. [16] [17] [18] We have observed in obese individuals that human AT EC (hATEC) from visceral AT exhibited higher senescent phenotype than subcutaneous AT and a decrease in PPARγ expression. 19 Together these evidence led us to hypothesis that disruption of PPARγ activity in senescent ECs contributes to the dysfunction of AT.
Using primary ECs freshly isolated from human AT, we characterized the FA handling machinery and ascertained the contribution of PPARγ in the regulation of endothelial FA uptake in human subcutaneous AT. In addition, we observed that, with the progression of senescence, activation of PPARγ drove differential response with a shift in the balance between FA fluxes and inflammation. These events were associated with a loss of PPARγ nuclear translocation and retention of FOXO1 (forkhead box protein O1).
Altogether, our observations underline the critical role of ATEC in human, in the regulation of FA fluxes that have to be taken into account in the comprehension of disorders associated with FA redistribution and lipotoxicity and the development of future therapies.
Materials and Methods

Human AT and Isolation of the Cell Subtypes
Subcutaneous abdominal ATs were obtained from healthy adult women undergoing dermolipectomy for esthetic purposes. Paired matched visceral and subcutaneous AT biopsies were obtained through a cohort study including nonobese and obese subjects. These studies were approved by the Institutional Review Boards. All subjects provided written informed consent. Protocol is registered at ClinicalTrials.gov (SENADIP; URL: http://www.clinicaltrials.gov. Unique identifier: NCT01525472). Clinical parameters of the donors from this protocol are summarized in Table I in the online-only Data Supplement.
AT was prepared as previously described to obtain stroma-vascular cells and mature adipocytes (hMA). 20 Native human progenitor (hPROG) and ECs from the stroma-vascular fraction were isolated by immunoselection/depletion; after the negative selection of immune cells (anti-CD45-depletion kit; StemCell technology), hPROG (CD31 NEG ), and endothelial (CD31 POS ) cells were then separated based on the immunoselection of CD31 POS population (Dynabeads CD31 Endothelial Cell; ThermoFisher Scientific).
EC Culture and Treatments
hATEC were grown in Endothelial Cell Growth Medium MV (Promo Cell) supplemented with 50 µg/mL gentamicine (GIBCO) on tissue culture dishes coated with 2 μg/cm 2 fibronectin (Millipore). Rosiglitazone (3 μmol/L) and GW9662 (10 μmol/L; for 12 hours) were added or not to the media.
For FA uptake experiments, hATEC or stroma-vascular fraction was starved for 4 hours in HBSS 0.1% BSA FA free and then incubated with BODIPY FL C16 (750 nmol/L final) for 2, 10, and 30 minutes. Incorporation of fluorescent C16 was then measured by flow cytometry.
Transmission Electron Microscopy
Samples were fixed with 2% glutaraldehyde in Sorensen buffer (0.1 mol/L, pH=7.4) for 1 hour, washed with the Sorensen phosphate buffer (0.2 mol/L) for 12 hours and postfixed with 1% OsO 4 in Sorensen buffer (Sorensen phosphate, 0.05 mol/L; glucose, 0.25 mol/L; OsO 4 , 1%) for 1 hour. Samples were dehydrated in an increasing ethanol series (up to 100% ethanol) and then with propylene oxide. Samples were embedded in epoxy resin (Epon 812). After 48 hours of polymerization at 60°C, ultrathin sections (70 nm) were mounted on 100 mesh collodion-coated copper grids and poststained with 3% uranyl acetate in 50% ethanol and with 8.5% lead citrate before being examined on an HT7700 Hitachi electron microscope at an accelerating voltage 80 KV.
Flow Cytometry
hPROG and hATEC were analyzed by flow cytometry using surface markers detected with antibodies CD45-BV510 (clone HI30, BioLegend), CD34-PerCP (clone 8612, BD), CD31-V450 (clone WM59, BD Horizon), FATP1-PE (clone 308420, R&D Systems), FATP4-APC (clone 342142, R&D Systems), and CD36-APC-Cy7 (Clone 5-271, BioLegend) or appropriate isotype controls. Cell suspensions were incubated with primary antibodies in PBS 2 mmol/L EDTA 0.5% BSA buffer. After a 20-minute incubation on ice, the cells were washed, resuspended, and analyzed on a FACS Canto II flow cytometer using Diva Pro software (BD Biosciences).
Transcriptional Analysis
Total RNA from hATEC and hPROG cells was purified using RNeasy Mini kit Plus (QIAGEN ) from human AT were isolated from the stroma-vascular fraction by flow cytometry (BD Influx cell sorter; BD Bioscience) using the following combination of antibodies: CD45-BV510 (clone HI30, Biolegend), CD34-PerCP (clone 8612, BD), and CD31-V450 (clone WM59, BD Horizon). Sorted cells were allowed to recover overnight in Endothelial Cell Growth Medium MV medium, before infection with lentiviral particles expressing SV40-large T antigen (Applied Biological Materials Inc) in the presence of protamine sulfate (4 μg/mL).
Statistical Analysis
Statistical analyses were performed using Prism (GraphPad Software). Comparisons between 2 independent groups were performed using 2-tailed nonparametric t test (Mann-Whitney test). For matched groups, after variance analysis (F test), paired parametric or nonparametric (Wilcoxon test) 2-tailed t test was performed. Comparisons between passaged cells were performed using nonparametric ANOVA tests and Sidak multiple comparison posttests. Correlations were obtained using Spearman coefficient (Spearman test; Figure 5 ). Differences were considered statistically significant when P<0.05.
Results
FA Handling Machinery in Native hATECs
To better characterize the human WAT microvascular cells, we performed transmission electron microscopy. As shown in Figure 1A , we observed that the microvascular endothelium from human AT is nonfenestrated. Therefore, active mechanisms are most likely to be involved in the WAT transendothelial FA fluxes. To further study the FA handling machinery . Transcript levels of genes encoding FA transporters (FATP) 1 (SLC27A1) and FATP3 (SLC27A3) were lower in hMA compared with hATEC and hPROG, whereas SLC27A4 (encoding FATP4) was similar in the 3 cell types ( Figure 1C ). Transcript levels of FABP4 (also known as aP2) and CD36 (also known as FAT) both PPARγ-targeted genes, as well as PPARγ itself, 22, 23 were as expected more expressed in hMA than in hPROG cells. In addition, they were also strongly expressed in hATEC ( Figure 1D ).
Finally, we performed flow cytometry to analyze cell surface expression of FATP1, FATP4, and CD36 in native hPROG and hATEC ( Figure 1E through 1I). FATP1 and FATP4 proteins were more exposed at the cell surface of hATEC than hPROG ( Figure 1E , 1F, and 1H) although mRNA levels were similar ( Figure 1C ). In parallel, the amount of CD36 protein was 40-fold higher at the cell surface of hATEC than hPROG ( Figure 1G and 1I). Therefore, native hATEC express actors of the FA handling machinery at levels comparable to adipocytes together with a significant exposure at the plasma membrane, supporting the role of hATEC in the regulation FA fluxes.
PPARγ Is Critical for the Regulation of FA Uptake in hATEC
We have previously shown using a cohort of obese individuals, that PPARγ expression level was decreased in EC from visceral AT compared with subcutaneous AT. 19 By flow cytometry performed on native hATEC, we observed that CD36 was also decreased at the surface of cells isolated from obese visceral AT (Ob Vs) compared with visceral AT from nonobese individuals (Ln Vs) and subcutaneous AT from obese individuals (Ob Sc; Figure 2A ). This FA coreceptor was described to be regulated by PPARγ activation in mouse endothelium 11 and human cardiac microvascular ECs in vitro. 24 To further analyze FA handling in native hATEC, we measured by flow cytometry their ability to uptake fluorescent FA (Bodipy FL C16) in vitro ( Figure 2B and 2C) . At 37°C hATEC efficiently incorporated FA. This phenomenon was not observed when the cells were maintained at 4°C ( Figure 2B ). In the presence of PPARγ agonist rosiglitazone at 37°C, a time-dependent increase in FA uptake was observed (rosi; Figure 2B and 2C) demonstrating that rosiglitazone treatment promotes FA uptake in hATEC.
To assess the contribution of PPARγ in the rosiglitazonemediated regulation of FA fluxes, we used a model of hATEC transduced with SV40-large T antigen (hATEC SV40 ). In hATEC SV40 the expression of EC markers including CD31 ( Figure 2D ) and VE-CADHERIN ( Figure 2E ; red) was maintained, but PPARγ mRNA level was 5× lower than in primary hATEC ( Figure 2F ). Low expression of PPARγ in hATEC SV40 was associated with a significantly lower expression of SLC27A1, FABP4, and CD36 ( Figure 2F and 2G), described to be PPARγ-dependent genes in other cell types. 22, 23, 25, 26 To note, no changes were observed for SLC27A4 ( Figure 2F ), which is not known as a PPARγ responsive gene. In hATEC SV40 , rosiglitazone treatment was not effective in increasing the uptake of FA ( Figure 2H ). Finally, treatment of hATEC with an irreversible inhibitor of PPARγ (GW9662) significantly decreased the impact of rosiglitazone on FA uptake ( Figure 2H ), strongly supporting the contribution of PPARγ in endothelial FA uptake in human AT.
Replicative Senescence Alters the Induction of Endothelial FA Uptake by PPARγ
To study the impact of EC senescence in PPARγ-mediated FA handling, we performed serial passaging (P) of primary hATEC and studied their ability to uptake FA over time. Uptake of Bodipy FL C16 was measured by flow cytometry in primary n=5 to 8 individuals. *P value to hATEC; #P value between hPROG and hMA. E-I, Surface levels of FATP1 (fatty acid transport protein; E-H) and FATP4 (F-H) and CD36 (G-I) were evaluated by flow cytometry in paired native hPROG (upper) and hATEC (lower). Representative histograms of cell count to mean fluorescence intensity (MFI) are shown (E-G) and MFI detection is presented. n=6 to 7 donors. #,*P<0.05; ##,**P<0.01; ###,***P<0.001. Data are presented as mean±SEM.
hATEC from P2 to P6 grown in the presence or not of rosiglitazone ( Figure 3A through 3C) . Noticeably, in untreated cells ( Figure 3A through 3C) hATEC exhibited a progressive decrease in FA uptake efficiency. Furthermore, although PPARγ activation ( Figure 3A through 3C) enhanced FA uptake at early passage (P2; Figure 2A ), the positive regulation was lost with cell passaging (P3/4 and P5/6; Figure 3B and 3C). Passaging and treatment with rosiglitazone had no noticeable effect on the amount of FATP1 and FATP4 presented at the cell surface ( Figure 3D through 3G) . In contrast, rosiglitazone treatment increased the amount of CD36 detected at the cell surface at early passage, but the positive regulation was progressively lost with passaging ( Figure 3H and 3I) . Treatment with rosiglitazone did not modify the cell surface expression of neither FATPs nor CD36 in hATEC SV40 ( Figure 3D through 3I ). This suggests that replicative senescence in hATEC abolishes the induction of FA uptake together with the presentation of CD36 at the plasma membrane mediated by PPARγ agonist.
Replicative Senescence Abrogates the Transcriptional Induction of FA Handling Machinery by PPARγ
Blockade of rosiglitazone-induced FA uptake in primary hATEC after passage 3/4 was not associated with a decrease in PPARγ expression ( Figure 4A ). However, serial passaging induced a rapid and significant upregulation of the senescence marker CDKN2A (encoding P16INK4) that reached up to 120-fold at P5/6 compared with P0. These levels were nevertheless significantly lower than in hATEC SV40 in which CDKN2A was >2000-fold higher than in primary P0 cells ( Figure 4B ). To explore the cause behind the loss of FA uptake in these cells, we performed transcriptional analyses on serially passaged (P0 to P6) primary hATEC grown in the presence or not of rosiglitazone. Treatment with rosiglitazone robustly induced the expression of SCL27A1, FABP4, and CD36 ( Figure 4C and 4D) in primary hATEC at P0. In hATEC SV40 , CD36 and FABP4 were responding to PPARγ activation although 5-to 10-fold less than in primary cells. In addition, rosiglitazone treatment failed to induce SLC27A1 and to maintain a PPARγ positive feedback loop in hATEC SV40 ( Figure 4C through 4E) . Finally, the involvement of PPARγ in rosiglitazone-mediated transcriptional regulation of SLC27A1, CD36, and FABP4, as well as PPARγ, was further confirmed by the use of the irreversible PPARγ antagonist GW9662 in primary hATEC ( Figure 4F ).
In contrast to the effect measured at P0, the induction SLC27A1, FABP4, and CD36 by rosiglitazone was progressively lost with passaging ( Figure 4C and 4D ). In addition, the feedback loop of PPARγ expression was also affected with an inversion of the balance between P1/2 and P3/4 ( Figure 4E ). SLC27A4, which expression is independent of PPARγ activity, was not significantly changed ( Figure 4C) . Noticeably, the pattern of this transcriptional deregulation coincided with the functional defect in FA uptake induction that progressively occurred between P2 and P5/6 ( Figure 3 ). These data support that the alteration of PPARγ transcriptional activity participates to the deregulation of FA handling in hATEC.
CDKN2A Accumulates in Native hATEC With Aging and Its Expression Correlates With a Decrease in Responsiveness to PPARγ Activation
The cyclin inhibitor P16INK4 (encoded by CDKN2A) has been shown in various systems to accumulate with senescence and aging. 6, 27 In a cohort of 28 individuals, we studied the expression pattern of CDKN2A in freshly isolated native hATEC from abdominal subcutaneous AT. Noticeably, we found that increasing levels of CDKN2A was positively correlated with aging ( Figure 5A ).
To further examine the link between hATEC senescence and their ability to respond and regulate FA fluxes, we performed correlation studies between the expression of CDKN2A and genes encoding the FA handling machinery, independently of replication cycle. hATEC transcriptional profile was evaluated under rosiglitazone treatment to mimic the activation of PPARγ that may occur in response to circulating lipid by-products and FA released from adipocytes. In primary hATEC, we observed a strong inversed correlation between CDKN2A level and the expression of PPARγ-target genes SLC27A1, CD36, and FABP4 ( Figure 5B, 5D , and 5E). The expression of PPARγ-independent FA transporter SLC27A4 was not correlated with CDKN2A pattern ( Figure 5C ). Thus, under increasing senescence pressure and aging, hATEC may progressively lose PPARγ-mediated ability to adapt and regulate FA fluxes.
Replicative Senescence Induces a Shift in the Response to PPARγ Activation in Primary hATEC
In parallel to the hampered induction of FA handling machinery that occurred in senescent hATEC, we observed an unexpected change in PPARγ transcriptional regulatory activity. Indeed, PPARγ activation by rosiglitazone at P0 efficiently repressed the expression of genes encoding mediators of senescence such as CCND1 (encoding cyclin D1) and IGFBP3 (insulin-like growth factor-binding protein 3). This effect was lost with passaging and even led to the induction of the latest. The expression of SIRT1 (sirtuin 1) and CDKN2A were not regulated by PPARγ activation ( Figure 6A ). In addition, the anti-inflammatory effect of PPARγ activation was also rapidly lost with passaging and instead triggered the induction of inflammatory mediators such as ICAM1 (intercellular adhesion molecule 1) and MCP1 (monocyte chemoattractant protein-1) together with a tendency to promote the upregulation of IL (interleukin)-6 and IL-8 at late passages ( Figure 6B ). These changes were likely dependent of PPARγ as this was not happening in hATEC SV40 ( Figure 6A and 6B) that exhibit low levels of the transcription factor.
PPARγ has been shown to antagonize NF-κB activity through the transcriptional regulation of NFKBIA (NF-κB inhibitor alpha; encoding IKB alpha), competitive inhibition on the promoter of target genes or NF-κB nuclear exclusion. 28, 29 In hATEC, there were no significant changes in NFKIA expression with passaging ( Figure 6C ). In addition, in this cell type, NFKIA expression was barely regulated by rosiglitazone treatment ( Figure 6D ). However, by immunofluorescence staining, we noticed that the number of nuclei positive for NF-κB-P65 subunit was increased by ≈3-fold in response to rosiglitazone in P6 hATEC, unlike what we observed in P2 hATEC ( Figure 6E and 6F) . This likely participated to the upregulation of known NF-κB target genes, including MCP1 and ICAM1. Altogether these observations support the notion that replicative senescence in hATEC may favor the emergence of proinflammatory and prosenescent events in response to PPARγ agonist rosiglitazone.
Nuclear Translocation of PPARγ Is Negatively Impacted by Replicative Senescence
Between P2 and P6, no change was observed in the expression of PPARγ at the transcript ( Figure 4A ) and protein level ( Figure 7A and 7B) that could account for the disrupted induction of its target genes. We thus assessed its subcellular localization by immunofluorescence staining. We observed that at early passage (P2), rosiglitazone treatment promoted a robust nuclear translocation of PPARγ. However, in rosiglitazone-treated P6 hATEC, PPARγ nuclear translocation was dramatically decreased (Figure 7C and 7G) an alteration that coincided with the decreased transcriptional activation of its target genes.
To further understand the decrease of nuclear PPARγ in P6 hATEC, we focused our attention on FOXO1, a transcription factor previously shown to antagonize PPARγ expression and activity. [30] [31] [32] At the transcript level, FOXO1 was slightly increased with passaging. However, no significant regulation was observed between early (P1/2) and late passages (P5/6) ( Figure 7D ). In contrast, FOXO1 protein revealed a trend to accumulate at late passage (P6; Figure 7E and 7F) . We then studied the subcellular localization of FOXO1 in combination with PPARγ by immunofluorescence staining in P2 and P6 hATEC treated or not with rosiglitazone ( Figure 7G through 7J). We noticed that at early passage (P2), rosiglitazone treatment decreased the proportion of nuclei single positive for FOXO1, as it may be expected about the reciprocal antagonistic effect of FOXO1 and PPARγ. This effect was significantly hampered at P6 (Figure 7H through 7J) , suggesting that in senescent hATEC, the retention of FOXO1 in the nuclei may contribute to alter PPARγ nuclear translocation or maintenance and its transcriptional activity.
Discussion
ECs lining the lumen of blood microvessels relay physiological and pathological clues to the surrounding tissue. It is now well accepted that their phenotype and function are as various as the organs in which they reside. 33 Among vascular beds, the role of EC from the AT (ATEC) remains poorly understood. Using human primary ATEC, we demonstrated that PPARγ activation increases FA uptake and FA handling Figure 6 . Replicative senescence promotes a transcriptional shift in response to PPARγ (peroxisome proliferator-activated receptor gamma) activation. Primary human adipose tissue endothelial cell (hATEC) from passage (P) 0 to 6 or hATEC SV40 were treated or not with rosiglitazone (3 μmol/L). Transcript levels of genes involved in senescence (A) and inflammatory response (B and D) were measured by qRT-PCR. Fold induction compared with untreated controls are represented in LOG2 scale ±SEM. hATEC n=4 donors; hATEC SV40 n=7 (4 clones). #P<0.05; ##P<0.01. *P<0.05, **P<0.01 compares to P0. C, mRNA level of NFKBIA (NF-κB inhibitor alpha) was measured by qRT-PCR and represented as relative to housekeeping gene (PPIB) in primary hATEC from P0 to P6. n=4 donors. E and F, NF-κB (nuclear factor-κB)-P65 subunit was detected by immunofluorescence (E, green) in native hATEC at P2 and P6 in the presence or not of rosiglitazone (rosi, 3 μmol/L). The number (%) of positive nuclei in rosiglitazone-treated hATEC compared with untreated controls are presented. #P<0.05 relative to untreated; *P<0.05 between P2 and P6. n=4 donors. Scale bar=40 μm.
machinery expression. Moreover, we showed that replicative senescence impacts hATEC responsiveness to ligand-mediated PPARγ activation resulting into a shift in EC phenotype from active FA transporter cells toward proinflammatory activated cells.
The microcirculation is an active component of AT homeostasis. Dense with each adipocyte surrounded by a capillary, the blood vasculature is thought to follow AT growth. Although blocking the growth of blood vessels was first proposed to reduce fat mass expansion and improve obesity, 34 this strategy is now debated. Indeed, ATEC play multiple roles and targeting their expansion during the early phase of diet-induced obesity aggravates insulin resistance in mice. 35 In addition, recent studies highlighted the role of endothelial extracellular matrix in AT distribution, expansion, and systemic response to high fat diet in zebrafish. 36 Other works performed in mice also reported a role for ECs in WAT browning and thermogenesis. 37 Another facet of EC function is the regulation of metabolic fluxes including FA. 8 In the AT, the microvascular endothelium is the platform for lipoproteins hydrolysis. Although blockade of FA transport toward the adipocytes may be beneficial to prevent excessive fat storage and obesity, it may also favor an increase in circulating lipids, ectopic lipid deposition in other organs and the emergence of cardiometabolic disorders, including type 2 diabetes mellitus and atherosclerosis. In the present study, we showed that native human ATEC robustly express molecules involved in FA handling at similar to higher levels than the surrounding adipocytes and progenitor cells. In particular, high levels of PPARγ-target genes FABP4 and CD36 commonly used as adipocyte markers and PPARγ itself were detected in hATEC. Our data also support that hATEC are key players in the appropriate handling of lipids and that this function is in part because of the activity of PPARγ and presentation at the cell surface of FA transporters including CD36. These data collected in primary human ATEC are in agreement with previous observations made in mice carrying endothelial deletion of Pparg. Indeed, these animals exhibited a decrease in endothelial CD36 expression and a restriction in fat mass gain when fed a high fat diet. 11 The central role of PPARγ in lipid homeostasis is underlined by the association of PPARγ mutations with lipodystrophy and metabolic syndrome conditions including dyslipidemia. In addition, PPARγ-activating therapies have shown beneficial outcome in restoring glucose and lipid homeostasis in subjects with type 2 diabetes mellitus. Here, we provide evidence that the consequences of ligand-mediated PPARγ activation in ECs is impacted by senescence. Senescence, evaluated by the expression of CDKN2A (encoding P16INK4), is increased with aging in native hATECs from subcutaneous AT. In vitro, the gradual increase in the expression of CDKN2A, because of serial passaging led to a progressive decrease in the metabolic response paralleled with an increase in the proinflammatory state in response to PPARγ agonist. To note, over a certain threshold of senescence, as observed in hATEC SV40 and in native hATEC from obese visceral AT, 19 the expression of PPARγ itself is dramatically reduced together with the one of CD36 at the cell surface. It is thus tempting to speculate that irreversible alterations of hATEC to handle FA may occur with disease and aging progression. PPARγ is regulated by lipid by-products and thus likely participates to the endothelial response and adaptation to FA fluxes coming both from the blood and adipocytes. Consequently, one can expect that the deregulation of endothelial PPARγ-dependent mechanisms would interfere both with the entry and the release of FA from the AT, ultimately favoring local and systemic dysfunctions. In our study, we addressed the impact of senescence on ligandmediated PPARγ response. To note, PPARγ also exhibits ligand-independent activity including the recruitment of corepressor complexes to the promoter of target genes. 29, 38 Previous studies also reported that PPARγ without agonist binding displays transcriptional activity. 39 The PPARγ N-terminal domain may contribute to this effect with a higher potency for the adipocyte-specific PPARγ2 compared with PPARγ1 isoform. 40 Furthermore, other works highlighted the role of kinases in ligand-independent activation of PPARγ. 41, 42 Thus, it is tempting to speculate that EC senescence, in addition to altering ligand-dependent PPARγ response, may also impact ligandindependent PPARγ activity. Further study will be needed to decipher the respective involvement of both mechanisms.
The change in endothelial ligand-induced PPARγ response may also affect the surrounding cells through the secretion of IGFBP3, previously shown to promote insulin resistance, 43, 44 as well as inflammatory cytokines MCP1, IL-6, and IL-8. It may be considered that the promotion of an inflammatory response in aging tissue may be a compensatory mechanism to adjust the surveillance of damaged and senescent cells. Indeed, the removal of senescent cells by genetic or pharmacological approaches has been shown to preserve AT function, insulin sensitivity, and improve metabolic parameters. [45] [46] [47] [48] The molecular events behind the differential response to PPARγ agonist with senescence remain to be identified and may result from profound and complex changes in cellular landscape. Indeed, the effect of ligand-dependent activation of PPARγ can be impacted by posttranslational modification of the receptor itself but also by the availability of a variety of cofactors that may account for the specificity of the response. 28, 49 In hATEC, senescence was not associated with major changes in PPARγ protein level. However, PPARγ presence in the nucleus was dramatically decreased and coincided with the accumulation of FOXO1. Noticeably, defects in FOXO1 expression and activity in various organs have been previously linked to the development of a panel of diabetes mellitus-associated complications. 50 In the AT, FOXO1 interferes with PPARγ activity [30] [31] [32] 51, 52 and antagonizes adipocyte differentiation. Mice expressing a dominant-negative form of FOXO1 under the control of the aP2 promoter showed improved glucose tolerance and insulin sensitivity. 51 Because aP2 is also expressed in ATEC, it is not excluded that some of these effects may be relayed through the endothelium. Similarly to PPARγ, FOXO1 activity is mainly controlled by posttranslational changes that modulate its cellular localization, nucleic acid, and protein binding affinity. It is thus likely that alteration of hATEC functionality with senescence results primarily from protein modifications that ultimately promote a breakage of homeostatic regulatory loop between PPARγ and FOXO1. 31, 32 As one of the first regulatory barrier between circulating metabolites and AT, ATEC have to be considered for the development of therapies aiming at restoring AT function and limiting lipotoxicity. Previous study in normoglycemic individuals has shown that rosiglitazone treatment had a positive impact on capillary density in periumbilical AT. 53 As underlined by the authors, this may participate to the improvement of insulin sensitivity through the delivery and removal of nutrient from the AT. Our study suggests that in addition, the positive effect of rosiglitazone on AT function may also be because of the regulation of transendothelial FA fluxes.
Combined with others, our data highlight the central role of AT endothelium in the maintenance of appropriate FA body distribution. However, the biological outcome of PPARγ-dependent mechanisms in ECs may vary with disease progression and aging, a phenomenon that has to be considered for the development of therapies. Although insulin sensitization by PPARγ agonists is efficient in metabolically active cells, we showed that ECs from the AT may also contribute to this response through the regulation of FA fluxes. Thus, in progress made to develop specific PPARγ-activating drugs, the endothelium should not be disregarded.
